Kolon TissueGene, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 48
- Market Cap
- -
- Website
- http://www.tissuegene.com
Study to Determine the Safety and Tolerability of TG-C in Subjects with Back Pain Due to Degenerative Disc Disease
Phase 1
Not yet recruiting
- Conditions
- Degenerative Disc Disease
- Interventions
- Biological: TG-C Low DoseBiological: TG-C High DoseBiological: TG-C Mid DoseBiological: Sham Control
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Kolon TissueGene, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06144970
A Study to Determine the Safety and Efficacy of TG-C in Subjects with Symptomatic Early Hip Osteoarthritis
Phase 2
Not yet recruiting
- Conditions
- Degenerative Osteoarthritis
- Interventions
- Biological: Placebo Control
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Kolon TissueGene, Inc.
- Target Recruit Count
- 255
- Registration Number
- NCT05276011
Study to Determine the Efficacy and Safety of TG-C in Subjects with Kellgren/Lawrence Grade 2 or 3 OA of the Knee
Phase 3
Active, not recruiting
- Conditions
- Degenerative Osteoarthritis
- Interventions
- Biological: Placebo Control
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Kolon TissueGene, Inc.
- Target Recruit Count
- 531
- Registration Number
- NCT03291470
- Locations
- 🇺🇸
Haresh Boghara, Red Oak, Texas, United States
🇺🇸Igor Grosman, Brooklyn, New York, United States
🇺🇸David Scott, Spokane, Washington, United States
A Study to Determine the Safety and Efficacy of TG-C in Subjects with Kellgren and Lawrence Grade 2 or 3 OA of the Knee
Phase 3
Active, not recruiting
- Conditions
- Degenerative Osteoarthritis
- Interventions
- Biological: Placebo Control
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Kolon TissueGene, Inc.
- Target Recruit Count
- 535
- Registration Number
- NCT03203330
- Locations
- 🇺🇸
Jeffrey Davis, Birmingham, Alabama, United States
🇺🇸Bradly Goodman, Birmingham, Alabama, United States
🇺🇸Saima Chohan, Phoenix, Arizona, United States
Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee
Phase 2
Completed
- Conditions
- Osteoarthritis, Knee
- Interventions
- Biological: TissueGene-CDrug: Normal Saline
- First Posted Date
- 2010-10-15
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Kolon TissueGene, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT01221441
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Advent Clinical Research, Pinellas Park, Florida, United States
🇺🇸Rothman Institute, Philadelphia, Pennsylvania, United States
Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee
Phase 1
Completed
- Conditions
- Osteoarthritis, Knee
- Interventions
- Biological: PlaceboBiological: TissueGene-C
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- Kolon TissueGene, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00599248
- Locations
- 🇺🇸
Commonwealth Orthopedics, Arlington, Virginia, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath